All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Market Valuation Set to Surge from USD 13.23 Billion in 2024 at a CAGR of 5.69% ...

About argenx SE and BioMarin Pharmaceutical Inc. argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan ...

March is considered one of the best months to visit Japan, thanks to its mild weather, colorful blooms, and vibrant cultural events. As winter wanes, plum and early cherry blossoms emerge in warmer ...

Want to relive that Japanese holiday, or get your eye in before you head overseas? You're in luck, because Melbourne is full of top-tier Japanese restaurants. Whether you’re craving sushi, ramen, ...

Currently, patients are commonly treated with Biomarin Pharmaceuticals’ Kuvan (sapropterin dihydrochloride), an enzyme cofactor therapy, or Palynziq (pegvaliase), an enzyme replacement therapy. Next ...

BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 0.61 ...

BioMarin's enzyme replacement therapy (ERT) business, particularly Naglazyme and Palynziq, has shown strong growth. The enzyme business grew by 12% year-over-year in 2024, with Palynziq growing by 17% ...

BioMarin Pharmaceutical Inc. (NASDAQ ... with Palynziq growing by 17% due to increased penetration in the US and Japan. Analysts believe that the ERT business could contribute to exceeding mid ...

On Monday, Oppenheimer analysts raised their outlook on BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN) stock, upgrading it from Perform to Outperform and setting a price target of $98.00.